Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models
Seyed Reza Banihashemi, Ali Es‐haghi, Mohammad Hossein Fallah Mehrabadi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Fatemeh Bayani, Negin Safaei Hashkavaei, Sareh Arjmand, et al.
Progress in Biophysics and Molecular Biology (2023) Vol. 178, pp. 32-49
Open Access | Times Cited: 43
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1120-1148
Open Access | Times Cited: 55
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 9
Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective
S. Furkan Demirden, Ilgin Kimiz‐Gebologlu, Suphi Ş. Öncel
ACS Omega (2024)
Open Access | Times Cited: 6
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges
Ziyi Bai, Dandan Wan, Tianxia Lan, et al.
ACS Nano (2024) Vol. 18, Iss. 36, pp. 24650-24681
Open Access | Times Cited: 6
Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2
Yifan Lin, Xuejiao Liao, Xuezhi Cao, et al.
Journal of Clinical Investigation (2025)
Open Access
Pre-clinical safety studies of intranasal virus-like particles based vaccine for prevention of COVID-19
Yana Yu. Chernoryzh, Валерия Михайловна Кондратьева, A. P. Malkova, et al.
Problems of Virology (2025)
Open Access
Mixed lipopeptide-based mucosal vaccine candidate induces cross-variant immunity and protects against SARS-CoV-2 infection in hamsters
Raj S. Patel, Diana Duque, Jegarubee Bavananthasivam, et al.
ImmunoHorizons (2025) Vol. 9, Iss. 2
Open Access
Nasal vaccines: solutions for respiratory infectious diseases
Rika Nakahashi-Ouchida, Kohtaro Fujihashi, Yosuke Kurashima, et al.
Trends in Molecular Medicine (2022) Vol. 29, Iss. 2, pp. 124-140
Open Access | Times Cited: 24
CHO cells for virus-like particle and subunit vaccine manufacturing
Zalma V. Sanchez-Martinez, Sergio P. Alpuche-Lazcano, Matthew Stuible, et al.
Vaccine (2024) Vol. 42, Iss. 10, pp. 2530-2542
Open Access | Times Cited: 4
Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections
Kevin J. Selva, Pradhipa Ramanathan, Ebene R. Haycroft, et al.
JCI Insight (2023) Vol. 8, Iss. 18
Open Access | Times Cited: 10
Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18–70 Years; A Randomized, Double-Blind Clinical Trial
Arash Mohazzab, Mohammad Hossein Fallah Mehrabadi, Ali Es‐haghi, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 112, Iss. 12, pp. 3012-3021
Closed Access | Times Cited: 10
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial
Saeed Erfanpoor, Seyed Reza Banihashemi, Ladan Mokhbaeralsafa, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress
Angelina Kovalenko, Ekaterina M. Ryabchevskaya, Ekaterina A. Evtushenko, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1701-1701
Open Access | Times Cited: 8
Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial
Masoud Solaymani Dodaran, Seyed Reza Banihashemi, Ali Es‐haghi, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 455-455
Open Access | Times Cited: 8
Mucosal vaccine development for respiratory viral infections
Yifan Lin, Zhenxiang Hu, Yang–Xin Fu, et al.
hLife (2023) Vol. 2, Iss. 2, pp. 50-63
Open Access | Times Cited: 8
Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread
Himanshu Ajmera, Sudarshan Singh Lakhawat, Naveen Malik, et al.
Current Protein and Peptide Science (2024) Vol. 25, Iss. 4, pp. 307-325
Closed Access | Times Cited: 2
Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial
Masoud Solaymani–Dodaran, Saeed Kalantari, Seyed Reza Banihashemi, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27370-e27370
Open Access | Times Cited: 2
Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines
Xuanxuan Zhang, Jialu Zhang, Si Chen, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 362-370
Open Access | Times Cited: 2
An overview of protein-based SARS-CoV-2 vaccines
Yogesh R. Suryawanshi
Vaccine (2023) Vol. 41, Iss. 42, pp. 6174-6193
Closed Access | Times Cited: 6
T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets
Alexandre E. Nowill, Manuel Caruso, Pedro O. de Campos‐Lima
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Analysis of immunological and biochemical parameters after booster dose vaccination using protein-based and inactivated virus vaccine for safety.
Esmat Malek, Mohammad Hossein Fallah Mehrabadi, Ali Es‐haghi, et al.
Heliyon (2024) Vol. 10, Iss. 22, pp. e40124-e40124
Open Access | Times Cited: 1
A review of the scientific literature on experimental toxicity studies of COVID-19 vaccines, with special attention to publications in toxicology journals
José L. Domingo
Archives of Toxicology (2024)
Open Access | Times Cited: 1
Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses
Maggie Jing Ouyang, Zhujun Ao, Titus Abiola Olukitibi, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1404-1404
Open Access | Times Cited: 3
Oral immunization with rVSV bivalent vaccine elicits protective immune responses, including ADCC, against both SARS-CoV-2 and Influenza A viruses
Maggie Jing Ouyang, Zhujun Ao, Titus Abiola Olukitibi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top